143 results on '"Moeck, Gregory"'
Search Results
2. Time–kill kinetics of oritavancin and comparator agents against Streptococcus pyogenes
3. Comparative activity of oritavancin against meticillin-resistant Staphylococcus aureus (MRSA) bloodstream isolates from Geneva University Hospital
4. Bisphosphonated fluoroquinolone esters as osteotropic prodrugs for the prevention of osteomyelitis
5. Inhibition of transcription in Staphylococcus aureus by a primary sigma factor-binding polypeptide from phage G1
6. Microbiological Characterization of VNRX-5236, a Broad-Spectrum β-Lactamase Inhibitor for Rescue of the Orally Bioavailable Cephalosporin Ceftibuten as a Carbapenem-Sparing Agent against Strains of Enterobacterales Expressing Extended-Spectrum β-Lactamases and Serine Carbapenemases
7. Oritavancin does not induce Clostridium difficile germination and toxin production in hamsters or a human gut model
8. Characterization of in vitro interactions between a truncated TonB protein from Escherichia coli and the outer membrane receptors FhuA and FepA
9. Stability studies of FhuA, a two-domain outer membrane protein from Escherichia coli
10. Comparative in vitro activity of oritavancin against Staphylococcus aureus strains that are resistant, intermediate or heteroresistant to vancomycin
11. Time–kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium
12. Topological analysis of the Escherichia coli ferrichrome-iron receptor by using monoclonal antibodies
13. Genetic insertion and exposure of a reporter epitope in the ferrichrome-iron receptor of Escherichia coli K-12
14. TonB-dependent iron acquisition: mechanisms of siderophore-mediated active transport†
15. Ligand-induced conformational change in the ferrichrome-iron receptor of Escherichia coli K-12
16. Two-Dimensional Crystallization on Lipid Layer: A Successful Approach for Membrane Proteins
17. An 8-Å Projected Structure of FhuA, A “Ligand-Gated” Channel of the Escherichia coli Outer Membrane
18. In vitro stepwise selection of reduced susceptibility to lipoglycopeptides in enterococci
19. Agar dilution minimum inhibitory concentrations under-represent oritavancin in vitro activity against staphylococci and enterococci
20. Assessment of the potential for oritavancin MIC changes among Staphylococcus aureus nasal carriage isolates following systemic oritavancin treatment in a phase 2 study in patients with acute bacterial skin and skin-structure infections
21. In vitro activity of Oritavancin against gram-positive pathogens isolated in Canadian hospital laboratories from 2011 to 2015
22. In vitro activities of oritavancin and comparators against meticillin-resistant Staphylococcus aureus (MRSA) isolates harbouring the novel mecC gene
23. Activity of oritavancin and comparators in vitro against standard and high inocula of Staphylococcus aureus
24. Synthesis and in vitro evaluation of bisphosphonated glycopeptide prodrugs for the treatment of osteomyelitis
25. Longitudinal analysis of the in vitro activity profile of oritavancin and comparator glycopeptides against Gram-positive organisms from Europe: 2005–2008
26. Oritavancin retains bactericidal activity in vitro against standard and high inocula of heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA)
27. Correlation between oritavancin and vancomycin minimum inhibitory concentrations in staphylococci
28. Oritavancin Disrupts Membrane Integrity of Staphylococcus aureus and Vancomycin-Resistant Enterococci To Effect Rapid Bacterial Killing
29. Assessment of Oritavancin Serum Protein Binding across Species
30. Characterization of the In Vitro Activity of Novel Lipoglycopeptide Antibiotics
31. Comparative in vitro activity of oritavancin against recent, genetically diverse, community-associated meticillin-resistant Staphylococcus aureus (MRSA) isolates
32. Comparative In Vitro Activity Profile of Oritavancin against Recent Gram-Positive Clinical Isolates
33. Impact of human serum albumin on oritavancin in vitro activity against Staphylococcus aureus
34. Inhibition of Transcription inStaphylococcus aureusby a Primary Sigma Factor-Binding Polypeptide from Phage G1
35. Impact of Human Serum Albumin on Oritavancin In Vitro Activity against Enterococci
36. Oritavancin Kills Stationary-Phase and Biofilm Staphylococcus aureus Cells In Vitro
37. Ultrastructural Effects of Oritavancin on Methicillin-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococcus
38. Bisphosphonated Benzoxazinorifamycin Prodrugs for the Prevention and Treatment of Osteomyelitis
39. Linking Bisphosphonates to the Free Amino Groups in Fluoroquinolones: Preparation of Osteotropic Prodrugs for the Prevention of Osteomyelitis
40. Assessment by Time-Kill Methodology of the Synergistic Effects of Oritavancin in Combination with Other Antimicrobial Agents against Staphylococcus aureus
41. Newly defined in vitro quality control ranges for oritavancin broth microdilution testing and impact of variation in testing parameters
42. Effect of Polysorbate 80 on Oritavancin Binding to Plastic Surfaces: Implications for Susceptibility Testing
43. TonB-dependent iron acquisition: mechanisms of siderophore-mediated active transport†
44. Cell Envelope Signaling in Escherichia coli
45. Construction of umu‐fhuA operon fusions to detect genotoxic potential by an antibody—cell surface reaction
46. TonB-dependent iron acquisition: mechanisms of siderophore-mediated active transport†.
47. TonB-dependent iron acquisition: mechanisms of siderophore-mediated active transport†.
48. Oritavancin Kills Stationary-Phase and Biofilm Staphylococcus aureusCells In Vitro
49. Ultrastructural Effects of Oritavancin on Methicillin-Resistant Staphylococcus aureusand Vancomycin-Resistant Enterococcus
50. An 8-Å Projected Structure of FhuA, A “Ligand-Gated” Channel of the Escherichia coliOuter Membrane
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.